Price G, Brenner M K, Prentice H G, Hoffbrand A V, Newland A C
Br J Cancer. 1987 Mar;55(3):287-90. doi: 10.1038/bjc.1987.55.
We have studied the cytotoxic effects of recombinant tumour necrosis factor and recombinant gamma interferon on primary cultures of leukaemia cells. The agents were added alone or in a combination to cells from 17 patients. Eleven had acute myeloblastic leukaemia (6 at presentation, 5 at relapse), 4 had acute lymphoblastic leukaemia, one had hairy cell leukaemia, and 2 had chronic myeloid leukaemia--one of whom was in myeloid blast transformation. Cells from patients with lymphoid malignancies or from the patient with chronic phase CML were not affected by either agent in any dose combination. In contrast, reduction of viability of myeloid blasts was weakly accelerated by TNF and gamma-interferon individually. Combination of the agents invariably produced enhanced killing and additive or synergistic effects were seen when 20-500 IU ml-1 of each cytokine was present. This sensitivity was also shown by blast cells from 5 patients with relapsed AML. We therefore suggest that trials of such combination therapy may be indicated in drug resistant or relapsed AML.
我们研究了重组肿瘤坏死因子和重组γ干扰素对白血病细胞原代培养物的细胞毒性作用。将这些药物单独或联合添加到17例患者的细胞中。其中11例患有急性髓细胞性白血病(6例初诊,5例复发),4例患有急性淋巴细胞性白血病,1例患有毛细胞白血病,2例患有慢性髓细胞性白血病——其中1例处于髓细胞母细胞转化期。淋巴系统恶性肿瘤患者或慢性期慢性髓细胞性白血病患者的细胞,在任何剂量组合下均不受这两种药物的影响。相比之下,肿瘤坏死因子和γ干扰素单独使用时,可轻微加速髓母细胞活力的降低。当每种细胞因子的浓度为20 - 500 IU/ml时,联合使用这两种药物总是会增强杀伤作用,并且会出现相加或协同效应。5例复发急性髓细胞性白血病患者的母细胞也表现出这种敏感性。因此,我们建议在耐药或复发的急性髓细胞性白血病中,可能需要进行这种联合治疗的试验。